ELIAVA Revenue and Competitors
Estimated Revenue & Valuation
- ELIAVA's estimated annual revenue is currently $3.8M per year.
- ELIAVA's estimated revenue per employee is $81,600
Employee Data
- ELIAVA has 46 Employees.
- ELIAVA grew their employee count by 7% last year.
ELIAVA's People
| Name | Title | Email/Phone |
|---|
ELIAVA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13M | 127 | 43% | N/A | N/A |
#2 | $11.2M | 110 | 62% | N/A | N/A |
#3 | $27.3M | 243 | 10% | N/A | N/A |
#4 | $26M | 237 | 25% | $11M | N/A |
#5 | $3.3M | 41 | -11% | N/A | N/A |
#6 | $11.6M | 114 | 24% | N/A | N/A |
#7 | $1.6M | 22 | 5% | N/A | N/A |
#8 | $34.9M | 548 | 18% | N/A | N/A |
#9 | $50.2M | 394 | -5% | N/A | N/A |
#10 | $13.6M | 243 | -10% | N/A | N/A |
What Is ELIAVA?
George Eliava Institute of Bacteriophages, Microbiology and Virology is world known institution in the field of bacteriophage research and applied microbiology. The main research activity of the institute is focused on isolation, selection and study of effective phages against human, animal and plant bacterial pathogens. Throughout more than 80 years history, the institute directed its activities towards elaboration, improvement and practical application of therapeutic, prophylactic and diagnostic bacteriophages against variety of bacterial infections.
keywords:N/A
N/A
Total Funding
46
Number of Employees
$3.8M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ELIAVA News
... Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, Eliava BioPreparations, Locus Biosciences,Inc, Pharmex Group,LLC and many more.
Bacteria-eating viruses: Researchers at the Eliava Institute of Bacteriophages in Tbilisi. It may seem strange after a pandemic that has killed...
Other Companies in Tbilisi
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.9M | 46 | -2% | N/A |
#2 | $13.3M | 47 | 4% | N/A |
#3 | $5.4M | 48 | -2% | N/A |
#4 | $5.4M | 48 | -2% | N/A |
#5 | N/A | 52 | 30% | N/A |